+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 28 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.

Age: 18Years - 75YearsAll GendersPhase 3
237 locations
S

Actively Recruiting

This research aims to assess the effectiveness and safety of adding oral anticoagulation OAC to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation POAF after isolated coronary artery bypass graft CABG surgery. The study is a prospective, multicenter, open-label, randomized trial comparing OAC with no OAC to evaluate the prevention of thromboembolic events and the risk of major bleeding. Participants are randomly assigned to either an OAC-based strategy using vitamin K antagonists or approved direct oral anticoagulants alongside antiplatelet therapy, or to an antiplatelet-only strategy. The anticoagulation treatment lasts for 90 days, with option for crossover to OAC if recurrent atrial fibrillation occurs after 30 days in the control group. Up to 500 patients may also participate in a digital health substudy using a wearable heart rhythm monitor for 30 days post-discharge. During the study, participants have follow-up visits at 30, 60, 90, and 180 days after randomization, including phone contacts and clinical assessments. Researchers will monitor outcomes such as death, stroke, transient ischemic attacks, myocardial infarction, thromboembolism, and bleeding events up to 180 days. Data from patients who decline randomization are collected in a parallel registry to compare baseline risk and treatment strategies.

Age: 18Years +All GendersPhase 3
106 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to explore how urinary and plasma biomarkers relate to changes in kidney function, specifically estimated glomerular filtration rate eGFR, in patients with pulmonary hypertension PH. PH is a serious and progressive condition linked to right heart dysfunction, heart failure, and increased risk of death. Kidney disease affects about 35% of PH patients and is associated with worse outcomes, potentially due to heart-related changes impacting the kidneys. The study observes two groups patients diagnosed with PH confirmed by right heart catheterization, with or without PH-specific treatment, and patients in whom PH was ruled out by the same test. No interventions or treatments are administered as part of this study. Instead, the focus is on collecting data and analyzing biomarkers related to kidney function and heart health over time. Participants will undergo right heart catheterization and will be followed for 12 months to monitor major adverse kidney events and worsening pulmonary hypertension or heart failure. Researchers will also track all-cause mortality, kidney function decline, and deaths related to pulmonary hypertension. No treatment is provided, but participants will be monitored through regular assessments and follow-up visits to help understand the connection between heart and kidney health in PH.

Age: 18Years +All Genders
2 locations
E

Actively Recruiting

Researchers are evaluating the safety and performance of the LivIQ leadless pacemaker system in patients who require ventricular pacing for conditions like bradycardia, AV block, or other cardiac rhythm disorders. This study is an open-label, prospective, single-arm international trial enrolling 325 subjects across multiple centers in the U.S., Europe, and Asia Pacific. It includes a specific sub-study designed to assess how well the device maintains atrioventricular synchrony AVS. Participants will receive the LivIQ leadless pacemaker, which is implanted directly into the right ventricle. The study includes scheduled visits at enrollment, device implant, pre-hospital discharge, and follow-ups at 1, 3, 6, and 12 months, continuing every 6 months until regional market approval. After U.S. approval, a remote visit at 24 months will check vital status. The AVS sub-study involves additional Holter monitoring at 1 and 6 months to evaluate device performance. Participants will undergo evaluations including physical examinations, device performance assessments, and quality of life questionnaires. Researchers will monitor serious adverse device effects, pacing and sensing adequacy, battery longevity, and survival rates over time. Follow-up includes in-person visits and remote monitoring to track safety and device function, with participation lasting up to about two years or more depending on market approvals.

Age: 18Years +All GendersPhase Not Applicable
43 locations
O

Actively Recruiting

The registry is designed to evaluate the outcomes, performance, and safety of BIOTRONIK devices used in conduction system pacing CSP through long-term data collected in real-world clinical settings. It includes patients who receive these devices as part of routine care to better understand their use and effects over time. The study is observational and collects data from unselected patients without intervention by the researchers. Participants receive BIOTRONIK devices for conduction system pacing, including the implantation of the Solia CSP S pacing lead for left bundle branch area pacing LBBAP. The study includes patients who are newly implanted, recently implanted but not yet discharged, or transitioning from a related study. The registry tracks device performance and safety over an average of 4 years through annual assessments. During the study, participants will undergo evaluations including the rate of device-related serious adverse events, success of acute implantation, capture type at implantation, long-term maintenance of pacing, and electrical parameters such as pacing threshold, sensing amplitude, and impedance. Participants will use the BIOTRONIK Home Monitoring system with the CardioMessenger device to support follow-up, which requires their willingness and ability to comply with study visits and monitoring over time.

Age: 18Years +All Genders
46 locations
P

Actively Recruiting

Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.

Age: 18Years +FEMALEPhase 3
138 locations
S

Actively Recruiting

Researchers are evaluating whether performing percutaneous coronary intervention PCI on all significant blockages in patients with non-ST-segment elevation myocardial infarction NSTEMI and multivessel coronary artery disease is better than treating only the main culprit lesion. This open-label, randomized, controlled, multicenter trial aims to compare these two approaches to understand which provides better outcomes for patients with this heart condition. Participants will be randomly assigned to one of two groups. One group will receive optimal medical therapy and PCI only on the culprit lesion, with no further intervention on other blockages unless certain emergency criteria occur. The other group will receive complete revascularization of all significant non-culprit lesions, either during the initial procedure, hospitalization, or within 45 days after the initial PCI. During the study, participants will be followed for an average of two years to monitor outcomes including cardiovascular death, rehospitalization for heart attacks, and other heart-related events. Researchers will also assess quality of life and complications such as bleeding, stroke, and kidney injury at various time points. The study involves regular evaluations and aims to gather comprehensive data to determine the best treatment strategy for these patients.

Age: 18Years +All GendersPhase Not Applicable
58 locations
P

Actively Recruiting

Researchers are conducting a global, prospective, multi-center post-market clinical follow-up study called MANTRA to monitor the safety and performance of CORCYM devices and accessories used for aortic, mitral, and tricuspid valve diseases in real-world settings. This umbrella protocol allows multiple sub-studies to be added, covering the sponsors entire cardiac surgery heart valve portfolio and including core lab assessments for some products. The study plans to enroll about 2150 subjects across up to 130 sites worldwide. The study includes three sub-studies the Aortic Sub-Study, the MitralTricuspid Sub-Study excluding Memo 4D, and the Memo 4D Sub-Study. Subjects diagnosed with valve diseases and considered suitable for treatment with specific CORCYM devices can participate in the corresponding sub-study. Follow-up visits are planned at discharge, 30 days post-implantation, and annually for up to 10 years. The Memo 4D sub-study involves additional echocardiogram imaging assessed by a core lab. Participants will provide informed consent and share baseline, procedural, hospitalization, discharge, and follow-up data during standard medical care. They will complete quality of life questionnaires at baseline, 30 days, and one year. Researchers will monitor device success at 30 days as the primary outcome and track mortality, adverse cardiovascular events, rehospitalizations, valve function, and patient outcomes up to 10 years. Safety and performance data will be collected continuously throughout the study.

All AgesAll Genders
52 locations
S

Actively Recruiting

This research aims to study the effects of repetitive acute Cyclosporine A CsA bolus therapy in patients with Takotsubo syndrome TTS who have a high risk of poor outcomes. Takotsubo syndrome may be caused by excess catecholamines leading to heart inflammation and damage. Currently, there is no proven treatment for TTS, and this phase 2 randomized controlled trial will evaluate whether CsA can reduce heart injury and improve heart function compared to placebo. Participants will be randomly assigned to receive either Cyclosporine A or a placebo intravenously at baseline, 12 hours, and 24 hours after study inclusion. The treatment is given as a bolus dose based on body weight. The study will compare these two groups to see if CsA reduces heart muscle damage and improves the hearts ejection fraction. Secondary measures include heart inflammation, hospital stay length, and quality of life over a one-year follow-up. During the study, participants will have blood tests to measure heart damage markers like Troponin T at multiple time points up to 30 days. Heart function and inflammation will be assessed through imaging and clinical evaluations. Researchers will monitor participants for cardiovascular events, symptoms, depression, anxiety, and PTSD scores at 30 days and one year. The total participation includes close monitoring during the acute phase and follow-up assessments for one year.

Age: 18Years +All GendersPhase 2
24 locations

1-10 of 28

1